K2 Medical Research Launches Innovative Clinical Trials Program in East Providence
EAST PROVIDENCE, R.I., May 19, 2025 /PRNewswire/ – K2 Medical Research has unveiled its new clinical trials program in East Providence, enhancing research opportunities in Southern New England. This private facility aims to confront pressing health challenges, particularly Alzheimer’s disease (AD), through pioneering clinical trials while ensuring top-notch patient care.
Coinciding with Clinical Trials Day on May 20, which honors the foundation of modern research set by James Lind in 1747, Dr. Daniel Sacchetti, Principal Investigator at K2, emphasized clinical trials’ vital role in transforming treatment approaches and fostering hope for current and future patients.
According to the Alzheimer’s Association, over 7 million Americans currently live with AD, supported by nearly 12 million caregivers, with the economic toll reaching $384 billion. In Rhode Island, approximately 22,000 residents are affected, with 11.4% of those aged 65 and older living with the disease.
K2’s East Providence site is actively enrolling participants in two different AD studies and another exploring a new medication for alcohol use disorder. The K2 team brings over three decades of combined experience in Alzheimer’s research and plans to host educational events to raise awareness.
For more information, visit k2med.com/k2eastprovidence or call 401-955-K2K2 (5252).
Note: The image is for illustrative purposes only and is not the original image associated with the presented article. Due to copyright reasons, we are unable to use the original images. However, you can still enjoy the accurate and up-to-date content and information provided.
